You are here
ARIETIS CORPORATION
UEI: DCSGCN3N8D87
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Development of a Dual-Targeting ClpP Activating Antibiotic
Amount: $1,000,000.00The World Health Organization has declared that antimicrobial resistance is one of the biggest threats to global health. It was estimated that by 2050, deaths due to drug resistant bacteria will excee ...
SBIRPhase II2023Department of Health and Human Services National Institutes of Health -
A New Approach to Treat Prosthetic Joint Infections with a ClpP Activating Antibiotic
Amount: $2,986,246.00The goal of this project is to develop a new class of urea-depsipeptide (UDEP) antibiotics to treat prosthetic joint infections (PJI). UDEPs kill bacteria through activation of the ClpP protease, caus ...
SBIRPhase II2021Department of Health and Human Services National Institutes of Health -
Bactericidal antibiotic for Vancomycin Resistant Enterococci
Amount: $3,718,043.00DESCRIPTIONprovided by applicantThe goal of the project is to develop a therapeutic against vancomycin resistant enterococcusVREThese infections are a serious health concern because antibiotic resista ...
SBIRPhase II2016Department of Health and Human Services National Institutes of Health -
Antibiotics for Recalcitrant Infection
Amount: $3,000,000.00DESCRIPTION provided by applicant The goal of the project is to develop a therapeutic capable of sterilizing recalcitrant chronic infections such as deep seated abscess osteomyelitis endocarditis ...
SBIRPhase II2015Department of Health and Human Services National Institutes of Health -
Antibiotics for Recalcitrant Infection
Amount: $300,000.00DESCRIPTION (provided by applicant): The goal of the project is to develop a therapeutic capable of sterilizing recalcitrant chronic infections such as deep-seated abscess, osteomyelitis, endocarditis ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
Narrow-spectrum Agents Acting against Helicobacter pylori
Amount: $3,000,000.00DESCRIPTION provided by applicant The goal of this project is to develop a therapeutic acting specifically against Helicobacter pylori the causative agent of peptic ulcer and gastric carcinoma Roughly ...
SBIRPhase II2013Department of Health and Human Services National Institutes of Health -
Compounds to treat Helicobacter pylori infection
Amount: $585,967.00DESCRIPTION (provided by applicant): The goal of this project is to discover lead compounds acting specifically against Helicobacter pylori, the causative agent of peptic ulcer and gastric carcinoma. ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
Narrow-spectrum Agents Acting against Helicobacter pylori
Amount: $297,456.00DESCRIPTION (provided by applicant): The goal of this project is to develop a therapeutic acting specifically against Helicobacter pylori, the causative agent of peptic ulcer and gastric carcinoma. Ro ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
2-adamantanamine Based Therapeutic for Recurrent Oropharyngeal Candidiasis
Amount: $598,147.00DESCRIPTION (provided by applicant): The goal of this Phase I project is to evaluate 2-adamantanamine compounds as a potential therapeutic to treat recurrent oropharyngeal candidiasis (OPC) in HIV pat ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health -
Therapy Against Recalcitrant C. albicans Infection
Amount: $2,984,770.00DESCRIPTION (provided by applicant): One of the important unresolved problems in fungal antimicrobial chemotherapy is the ineffectiveness of existing therapeutics against cells that do no exist in a r ...
SBIRPhase II2010Department of Health and Human Services National Institutes of Health
